Analysts' average 12-month price target for Structure Therapeutics is $94.
Get informed when a big investor buys or sells
+ Follow$49.74
3 analysts in the last 4 months
High: $111 | Low: $70
No recommendations in the last 4 months.
Structure Therapeutics posts a target price of $94. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
A target price of $94 for GPCR means covering analysts, on average, see the stock 89.0% upside of $49.74 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.
Context for GPCR's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Structure Therapeutics's other metric pages and overview cover the third.